Abemaciclib

128 interactions 114 explained in plain English 328 cited references
Also sold as: Verzenio Verzenio®
About Abemaciclib

Abemaciclib is used in combination with an aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor-positive, early breast cancer. Abemaciclib is also used along with fulvestrant (Faslodex) to treat a certain type of hormone receptor-po… Read the full Abemaciclib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 11, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Mumps Virus Vaccine, Live Rubella Virus Vaccine, Live Smallpox Monkeypox Vaccine Typhoid Vaccine Varicella Virus Vaccine, Live Yellow Fever Vaccine
12 Contraindicated 75 Major 41 Moderate
All (128) Contraindicated (12) Major (75) Moderate (41)

Major

Abemaciclib Vorasidenib Voranigo Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Abemaciclib Voxelotor Oxbryta Explained Increased exposure of sensitive CYP3A4 substrates Details Abemaciclib Ketoconazole Topical Extina® Foam Increased abemaciclib exposure Details Abemaciclib Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Abemaciclib Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Abemaciclib Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Abemaciclib Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details

Moderate

Abemaciclib Trospium / Xanomeline Cobenfy Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Abemaciclib Aprepitant Aponvie Explained Increased abemaciclib plasma concentration Details Abemaciclib Artemether Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Abemaciclib Atazanavir Reyataz Explained Increased abemaciclib plasma concentration Details Abemaciclib Boceprevir Explained Increased abemaciclib plasma concentration Details Abemaciclib Ciprofloxacin Explained Increased abemaciclib plasma concentration Details Abemaciclib Clarithromycin Biaxin Explained Increased abemaciclib plasma concentration Details Abemaciclib Cobicistat Tybost Explained Increased abemaciclib plasma concentration Details Abemaciclib Conivaptan Vaprisol Explained Increased abemaciclib plasma concentration Details Abemaciclib Crizotinib Xalkori Explained Increased abemaciclib plasma concentration Details Abemaciclib Cyclosporine Atopica Explained Increased abemaciclib plasma concentration Details Abemaciclib Diltiazem Cardizem Explained Increased abemaciclib plasma concentration Details Abemaciclib Dronedarone Multaq Explained Increased abemaciclib plasma concentration Details Abemaciclib Erythromycin Erythrocin Stearate Explained Increased abemaciclib plasma concentration Details Abemaciclib Fluconazole Diflucan Explained Increased abemaciclib plasma concentration Details Abemaciclib Fluvoxamine Explained Increased abemaciclib plasma concentration Details Abemaciclib Fosnetupitant Explained Increased abemaciclib plasma concentration Details Abemaciclib Idelalisib Zydelig Explained Increased abemaciclib plasma concentration Details Abemaciclib Imatinib Gleevec Explained Increased abemaciclib plasma concentration Details Abemaciclib Indinavir Explained Increased abemaciclib plasma concentration Details Abemaciclib Itraconazole Sporanox Explained Increased abemaciclib plasma concentration Details Abemaciclib Kratom Explained Increased CYP3A substrate exposure Details Abemaciclib Letermovir Prevymis Explained Increased abemaciclib plasma concentration Details Abemaciclib Lopinavir Explained Increased abemaciclib plasma concentration Details Abemaciclib Mavacamten Camzyos Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Abemaciclib Nefazodone Explained Increased abemaciclib plasma concentration Details Abemaciclib Nelfinavir Viracept Explained Increased abemaciclib plasma concentration Details Abemaciclib Netupitant Explained Increased abemaciclib plasma concentration Details Abemaciclib Nilotinib Explained Increased abemaciclib plasma concentration Details Abemaciclib Posaconazole Noxafil Explained Increased abemaciclib plasma concentration Details Abemaciclib Rilzabrutinib Wayrilz Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Abemaciclib Ritonavir Norvir Explained Increased abemaciclib plasma concentration Details Abemaciclib Saquinavir Explained Increased abemaciclib plasma concentration Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.